Literature DB >> 17058065

[Neovascular glaucoma: aetiology, pathogenesis and treatment].

K U Löffler1.   

Abstract

Neovascular glaucoma, as a typical secondary glaucoma, is due to ocular or (earlier) systemic diseases. The formation of a fibrovascular membrane on the anterior surface of the iris (rubeosis iridis) and extending into the chamber angle leads to irreversible obliteration of the outflow system, with a corresponding rise in intraocular pressure. The most frequent cause is retinal ischaemia resulting either from vascular occlusion or from diabetic alterations. The differential diagnosis must include acute angle-closure glaucoma and uncontrolled open-angle glaucoma. Treatment is aimed at eliminating the actual cause or at least reducing the risk factors (e.g. by retinal laser coagulation), or consists in cyclodestructive procedures. Medicamentous therapy comprises anti-inflammatory agents (steroids, cycloplegic agents) and substances that reduce the production of aqueous humour (carbonic anhydrase antagonists, beta blockers). In the near future, antiangiogenic medication might be another effective option. For end-stage neovascular glaucoma, the implantation of drainage devices is also discussed.

Entities:  

Mesh:

Year:  2006        PMID: 17058065     DOI: 10.1007/s00347-006-1431-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  21 in total

1.  Neovascular glaucoma and sarcoidosis.

Authors:  B J Gaskin; H V Danesh-Meyer
Journal:  Eye (Lond)       Date:  2005-05       Impact factor: 3.775

Review 2.  Anterior segment ischemia secondary to carotid occlusive disease.

Authors:  R P Mills
Journal:  J Clin Neuroophthalmol       Date:  1989-09

3.  Long-term results of Molteno implant insertion in cases of neovascular glaucoma.

Authors:  Sean G Every; Anthony C B Molteno; Tui H Bevin; Peter Herbison
Journal:  Arch Ophthalmol       Date:  2006-03

Review 4.  [Radiation-induced retinopathy].

Authors:  L Lumbroso; R Dendale; A Fourquet; L Desjardins
Journal:  Cancer Radiother       Date:  2002-09       Impact factor: 1.018

5.  Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone.

Authors:  J B Jonas; J K Hayler; A Söfker; S Panda-Jonas
Journal:  J Glaucoma       Date:  2001-08       Impact factor: 2.503

6.  [Molteno/von Denffer drainage implants in therapy-refractory glaucomas].

Authors:  M Jähne; G Sulzer
Journal:  Klin Monbl Augenheilkd       Date:  2005-10       Impact factor: 0.700

Review 7.  The glaucomas.

Authors:  A L Coleman; L Brigatti
Journal:  Minerva Med       Date:  2001-10       Impact factor: 4.806

Review 8.  Glaucoma drainage devices: a systematic literature review and current controversies.

Authors:  Chian-Huey Hong; Analisa Arosemena; David Zurakowski; Ramesh S Ayyala
Journal:  Surv Ophthalmol       Date:  2005 Jan-Feb       Impact factor: 6.048

9.  Clinical experience in the management of neovascular glaucoma.

Authors:  Tung-Mei Kuang; Catherine Jui-Ling Liu; Ching-Kuang Chou; Wen-Ming Hsu
Journal:  J Chin Med Assoc       Date:  2004-03       Impact factor: 2.743

10.  Intravitreal triamcinolone acetonide as adjunctive treatment for neovascular glaucoma.

Authors:  Maria Teresa Brizzi Chizzotti Bonanomi; Remo Susanna
Journal:  Clinics (Sao Paulo)       Date:  2005-08-29       Impact factor: 2.365

View more
  2 in total

1.  Important Risk Factors Were Not Included.

Authors:  Dieter Schmidt
Journal:  Dtsch Arztebl Int       Date:  2017-04-21       Impact factor: 5.594

Review 2.  Ocular associations of diabetes other than diabetic retinopathy.

Authors:  V Swetha E Jeganathan; Jie Jin Wang; Tien Yin Wong
Journal:  Diabetes Care       Date:  2008-09       Impact factor: 19.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.